467 related articles for article (PubMed ID: 28349291)
1. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
3. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of [
Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M
Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872
[TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of [
Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
10.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
12. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
14. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
15. Physiological Biodistribution of
Özgüven S; Filizoğlu N; Kesim S; Öksüzoğlu K; Şen F; Öneş T; İnanır S; Turoğlu HT; Erdil TY
Mol Imaging Radionucl Ther; 2021 Feb; 30(1):39-46. PubMed ID: 33586406
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B
Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [
Raheem SJ; Salih AK; Garcia MD; Sharpe JC; Toosi BM; Price EW
Bioconjug Chem; 2023 Mar; 34(3):549-561. PubMed ID: 36800496
[TBL] [Abstract][Full Text] [Related]
18. [Value of
Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385
[TBL] [Abstract][Full Text] [Related]
19. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
20. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
